This trial is evaluating whether Abemaciclib will improve 1 primary outcome and 4 secondary outcomes in patients with Biliary Tract Carcinoma. Measurement will happen over the course of approximately 7 months.
This trial requires 24 total participants across 1 different treatment group
This trial involves a single treatment. Abemaciclib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The majority of stage 3+ cancers can be cured, but patients with cancer of the pancreas, uterus, and testes are not likely to be completely cured. Most patients with stage 3 carcinoma of the mouth and oropharynx, stomach, lung, and colon, and some patients with stage 4 carcinomas can be cured." - Anonymous Online Contributor
"The hallmark symptom of carcinoma is a mass or mass like growth in the abdominal cavity or gastrointestinal tract. When tumours are found in the breasts, they will often cause nipple enlargement and pain. Rarely, a carcinoma can be mistaken for a lump or mass in another part of the body. A carcinoma can sometimes be identified in a screening programme using blood tests or medical imaging. The signs of carcinoma can cause a lump in the throat. Symptoms include painless difficulty swallowing, weight loss and the feeling of something sticking in the throat." - Anonymous Online Contributor
"The most common cancer is that of the lung. Lung cancer is caused by the smoking of tobacco, which is also one of the causes of lung calcification. The development of lung parenchymal carcinoma can be caused by tobacco smoking or by a previous radiotherapy of the chest. There are more than one million people dying per year due to lung cancer." - Anonymous Online Contributor
"To identify common risk factors for carcinoma, we studied the prevalence of these factors in an unselected case-control study in a rural, inner city community in New Mexico. Results of our study indicate that cigarette smoking, alcohol drinking, and a low serum cholesterol level may increase the risk for lung cancer when analyzed as a composite of smoking, drinking, and serum cholesterol level. We report the highest prevalences of these risk factors in this unselected population of inner city residents. In a recent study, findings support the hypothesis that cigarette smoking, alcohol drinking, and a low serum cholesterol level increase the risk for lung cancer." - Anonymous Online Contributor
"Only a small number of cancers do not require therapy, which mostly are localized lesions. Radical prostatectomy and curative resections are appropriate for most localized prostate cancers. For the remaining cancers, radiation therapy is the most common form of treatment. Radiation therapy can be used in most situations. Targeted therapy is becoming increasingly common for some rare cancers. Rarely, surgery, cryotherapy, chemotherapy, or biotherapy is used." - Anonymous Online Contributor
"Carcinoma should be considered only as a serious concern if it develops early, or if the person is young. The current incidence of carcinoma is unlikely to be increasing substantially in developed countries." - Anonymous Online Contributor
"[Clinical and biomedical research has the potential to improve the care and survival of patients with carcinoma] (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Medline&term=carcinoma&mode=map). For more information, see Cancer. © 2015 American Cancer Society." - Anonymous Online Contributor
"A phase I study for first-line metastatic breast cancer suggests that abemaciclib is effective with no toxicity, including no myelotoxicity. The compound appears to bind strongly to the human target and to mediate its effect by inhibition of the protein (phospholipase C-gamma1, Ca( 2+ ) /calmodulin-calmodulin-dependent protein kinase II). These promising results have led to the development of abemaciclib for use in phase II clinical trials. The phase I study also provides support for clinical trials using the compound as a first line treatment for patients with hormone receptor negative metastatic breast cancer and as a combination with endocrine and targeted therapies." - Anonymous Online Contributor
"In clinical trials, abemaciclib has been found to be well tolerated and highly effective in a broad range of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer)s, including some resistant to previous therapies and/or aromatase inhibitor-refractory cancers. In addition, abemaciclib demonstrated superiority over lapatinib in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab. Abemaciclib has a broad spectrum of activity. The combination with rucaparib is being studied in patients with HER2-positive metastatic breast cancer who previously received trastuzumab and lapatinib. Moreover, it is being studied in patients with previously treated estrogen receptor-positive metastatic breast cancer." - Anonymous Online Contributor
"Although ABL is highly effective at inhibiting PFS and TTP in those with newly diagnosed breast cancer, it does not appear to improve QoL in those with HR+ advanced breast cancer." - Anonymous Online Contributor
"Abemaciclib causes nausea in approximately 10% of patients. Abemaciclib is not associated with diarrhea. Patients should not stop taking abemaciclib and resume treatment if experiencing nausea. All patients should be warned of rare but potentially fatal infusion reactions (<0.01%)." - Anonymous Online Contributor
"Results of this phase II trial were encouraging. Patients with early HER2-positive [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) responded to abemaciclib. More information about this and more data is needed to further determine what role abemaciclib might have in treatment of advanced cancer." - Anonymous Online Contributor